Key Points
- Insider sale: Ije Nwokori sold 204,051 shares on April 15 at GBX 66, a transaction valued at £134,673.66.
- The stock trades around GBX 67.30 with a 52‑week range of GBX 50.60–100.87 and a market cap of ~£650.6m, while valuation and balance‑sheet metrics show a high P/E of 39.6 and a debt‑to‑equity ratio of 120.66.
- Analysts are mixed (two Buys, two Holds) with a consensus rating of Moderate Buy and a reported consensus price target of GBX 6,000.
Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori sold 204,051 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of GBX 66, for a total transaction of £134,673.66.
Ije Nwokori also recently made the following trade(s):
- On Tuesday, April 14th, Ije Nwokori purchased 232 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 65 per share, for a total transaction of £150.80.
- On Wednesday, February 11th, Ije Nwokori bought 219 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 69 per share, with a total value of £151.11.
Dr. Martens Trading Up 1.4%
Shares of Dr. Martens stock opened at GBX 67.30 on Friday. The stock's 50-day simple moving average is GBX 65.51 and its 200 day simple moving average is GBX 75.70. Dr. Martens plc has a 52-week low of GBX 50.60 and a 52-week high of GBX 100.87. The company has a debt-to-equity ratio of 120.66, a quick ratio of 1.13 and a current ratio of 2.18. The stock has a market capitalization of £650.61 million, a P/E ratio of 39.59, a P/E/G ratio of 6.40 and a beta of 0.24.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on DOCS shares. Royal Bank Of Canada reiterated a "sector perform" rating on shares of Dr. Martens in a research note on Tuesday, February 3rd. Berenberg Bank reaffirmed a "buy" rating on shares of Dr. Martens in a report on Tuesday, January 27th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Dr. Martens presently has a consensus rating of "Moderate Buy" and a consensus price target of GBX 6,000.
Check Out Our Latest Analysis on DOCS
Dr. Martens Company Profile
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
